0 citations
Sofosbuvir/Velpatasvir for Treatment of Hepatitis C Virus in Asia: An Open-Label, Phase 3 Study
SSRN Electronic Journal2018
Citations Over Time
Lai Wei, Seng Gee Lim, Qing Xie, Kính Nguyen Văn, Teerha Piratvisuth, Yan Huang, Shanming Wu, Ming Xu, Hong Tang, Jun Cheng, Hùng Lê Mạnh, Yanhang Gao, Zhuangbo Mou, Abhasnee Sobhonslidsuk, Xiaguang Dou, Satawat Thongsawat, Yuemin Nan, Chee‐Kiat Tan, Qin Ning, Hoi Poh Tee, Yimin Mao, Luisa M. Stamm, Sophia Lu, Hadas Dvory‐Sobol, Hongmei Mo, Diana M. Brainard, Yongfeng Yang, Long Van Dao, Guiqiang Wang, Tawesak Tanwandee, Peng Hu, Pisit Tangkijvanich, Lunli Zhang, Zhi Gao, Feng Lin, Thi Tuyet Phuong Le, Jia Shang, Guozhong Gong, Jun Li, Minghua Su, Zhongping Duan, Rosmawati Mohamed, Jin Hou, Jidong Jia
Related Papers
- → Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients(2022)6 cited
- → Health-related quality of life in children with hepatitis C viral (HCV) infection treated with sofosbuvir and ribavirin(2017)1 cited
- Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.(2020)
- → Faculty Opinions recommendation of Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.(2013)